REZUM; A Water Vapor Thermal Therapy; as A Minimal Invasive Technique vs. Transurethral Resection of Prostate in saline as The Gold Standard in Management of Benign Prostatic Hyperplasia. A prospective randomized study
Abstract
Management of BPH involves a variety of treatment options tailored on patient’s symptoms, prostate size, and overall health status. Traditional treatments have ranged from watchful waiting for mild symptoms to medication and surgery for more severe cases.
Evaluation of REZUM and clarifying its position in the armamentarium of the surgical treatments of benign prostatic hyperplasia (BPH) of 30–90 g size, through comparing it with transurethral resection of prostate in saline (TURis); the evolution of the known gold standard TURP; regarding efficacy & safety.
It is a Prospective cohort interventional study on BPH patients treated with TURis or REZUM within a year from April 2022 till March 2023 in Ain-shams university hospital, National Institute of Nephrology & Urology and Katameya Clinic hospital, resp. The research involved (57) patients allocated in two groups, group A patients underwent TURis (34) and group B patients underwent REZUM (23). The comparison items were international prostate symptom score (IPSS), quality of life (QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR), operative time, catheter time, hospital stay for efficacy and using the incidence of complications and affection over sexual function for safety.
Rezum significantly changed IPSS from the baseline score by -53.5%, QoL score by -60%, Qmax by + 63.5%, PVR by -56.7% and Ejaculatory function improved by 7.2% all at 6 months of follow up. On the other hand, these outcomes in efficacy…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.